Literature DB >> 15690864

Vitamin C deficiency in cancer patients.

Catriona R Mayland1, Michael I Bennett, Keith Allan.   

Abstract

PURPOSE: To assess the prevalence of vitamin C deficiency within a group of hospice patients. To assess the relationship between plasma vitamin C, dietary intake and subsequent survival.
METHODS: Patients with advanced cancer were recruited from a large hospice. Data were collected on demographic details, physical functioning and smoking history. An estimate was obtained of the number of weekly dietary portions consumed equivalent to 40 mg of vitamin C, the recommended daily intake. Plasma vitamin C was measured by a single blood sample. The study had local ethical approval.
RESULTS: Fifty patients were recruited (mean age 65.2 years, 28 female). Plasma vitamin C deficiency was found in 15 (30%). Dietary intake of vitamin C was correlated to plasma vitamin C (r=0.518, P<0.0001). Low dietary intake, low albumin, high platelet count, high CRP level and shorter survival were all significantly associated with low plasma vitamin C concentrations (<11 micromol/L). There was no correlation between plasma vitamin C, smoking history or physical functioning.
CONCLUSION: Vitamin C deficiency is common in patients with advanced cancer and the most important factors determining plasma levels are dietary intake and markers of the inflammatory response. Patients with low plasma concentrations of vitamin C have a shorter survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15690864     DOI: 10.1191/0269216305pm970oa

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  63 in total

1.  Subcellular basis of vitamin C protection against doxorubicin-induced changes in rat cardiomyocytes.

Authors:  Ana Ludke; Anita K Sharma; Ashim K Bagchi; Pawan K Singal
Journal:  Mol Cell Biochem       Date:  2011-09-22       Impact factor: 3.396

Review 2.  Targeting cancer vulnerabilities with high-dose vitamin C.

Authors:  Bryan Ngo; Justin M Van Riper; Lewis C Cantley; Jihye Yun
Journal:  Nat Rev Cancer       Date:  2019-05       Impact factor: 60.716

3.  Antioxidants and Other Micronutrients in Complementary Oncology.

Authors:  Uwe Gröber
Journal:  Breast Care (Basel)       Date:  2009-02-20       Impact factor: 2.860

4.  Vitamin C increases DNA breaks and suppresses DNA damage-independent activation of ATM by bleomycin.

Authors:  Blazej Rubis; Michal W Luczak; Casey Krawic; Anatoly Zhitkovich
Journal:  Free Radic Biol Med       Date:  2019-03-26       Impact factor: 7.376

5.  Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

Authors:  Thomas E Ichim; Boris Minev; Todd Braciak; Brandon Luna; Ron Hunninghake; Nina A Mikirova; James A Jackson; Michael J Gonzalez; Jorge R Miranda-Massari; Doru T Alexandrescu; Constantin A Dasanu; Vladimir Bogin; Janis Ancans; R Brian Stevens; Boris Markosian; James Koropatnick; Chien-Shing Chen; Neil H Riordan
Journal:  J Transl Med       Date:  2011-03-04       Impact factor: 5.531

Review 6.  Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly.

Authors:  Niraj Shenoy; Edward Creagan; Thomas Witzig; Mark Levine
Journal:  Cancer Cell       Date:  2018-08-30       Impact factor: 31.743

7.  TET family dioxygenases and the TET activator vitamin C in immune responses and cancer.

Authors:  Xiaojing Yue; Anjana Rao
Journal:  Blood       Date:  2020-09-17       Impact factor: 22.113

Review 8.  Vitamin C in Stem Cell Reprogramming and Cancer.

Authors:  Luisa Cimmino; Benjamin G Neel; Iannis Aifantis
Journal:  Trends Cell Biol       Date:  2018-04-30       Impact factor: 20.808

9.  Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine.

Authors:  Minmin Liu; Hitoshi Ohtani; Wanding Zhou; Andreas Due Ørskov; Jessica Charlet; Yang W Zhang; Hui Shen; Stephen B Baylin; Gangning Liang; Kirsten Grønbæk; Peter A Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-29       Impact factor: 11.205

10.  High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis.

Authors:  Chang-Hwan Yeom; Gunsup Lee; Jin-Hee Park; Jaelim Yu; Seyeon Park; Sang-Yeop Yi; Hye Ree Lee; Young Seon Hong; Joosung Yang; Sukchan Lee
Journal:  J Transl Med       Date:  2009-08-11       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.